MicroRNA‑4491 enhances cell proliferation and inhibits cell apoptosis in non‑small cell lung cancer via targeting TRIM7

Han,Fei; Chen,Gang; Guo,Yi; Li,Bo; Sun,Yanlong; Qi,Xiangqian; Tian,Hanji; Zhao,Xinfei; Zhang,Hongguang

doi:10.3892/ol.2021.12852

MicroRNA‑4491 enhances cell proliferation and inhibits cell apoptosis in non‑small cell lung cancer via targeting TRIM7

Authors:
- Fei Han
- Gang Chen
- Yi Guo
- Bo Li
- Yanlong Sun
- Xiangqian Qi
- Hanji Tian
- Xinfei Zhao
- Hongguang Zhang
View Affiliations

Affiliations: Department of Thoracic Surgery, Shanxi Provincial Cancer Hospital, Taiyuan, Shanxi 030013, P.R. China, Department of Respiratory Diseases, Shanxi Provincial Cancer Hospital, Taiyuan, Shanxi 030013, P.R. China, Department of Thoracic Radiotherapy, Shanxi Provincial Cancer Hospital, Taiyuan, Shanxi 030013, P.R. China, Taiyuan Jinyu Clinical Laboratory, Taiyuan, Shanxi 030013, P.R. China
Published online on: June 7, 2021 https://doi.org/10.3892/ol.2021.12852
Article Number: 591
Copyright: © Han et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs) are involved in the development of non‑small cell lung cancer (NSCLC). However, the biological roles of several aberrantly expressed miRNAs have not been explored yet. In the present study, miR‑4491 was identified as a novel upregulated miRNA in NSCLC tissues and cell lines. Downregulation of miR‑4491 by a miR‑4491 inhibitor inhibited the proliferation and triggered the apoptosis of NSCLC cells. Tripartite motif containing 7 (TRIM7), a tumor suppressor gene expressed in NSCLC, was demonstrated in the present study to be directly targeted by miR‑4491. This finding was verified by bioinformatics analysis, reverse transcription‑quantitative PCR, western blotting and dual luciferase reporter assays. Furthermore, downregulation of miR‑4491 inactivated nuclear factor‑κB signaling via induction of TRIM7. In addition, TRIM7 silencing attenuated the effect of miR‑4491 inhibitor in NSCLC cells. The decreased TRIM7 level in NSCLC tissues was negatively correlated with miR‑4491 expression in NSCLC tissues. In conclusion, the findings from this study demonstrated that miR‑4491 expression was upregulated in NSCLC tissues and cells and that miR‑4491 may promote NSCLC progression via targeting TRIM7.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
3	Cersosimo RJ: Lung cancer: A review. Am J Health Syst Pharm. 59:611–642. 2002. View Article : Google Scholar : PubMed/NCBI
4	Inamura K: Lung cancer: Understanding its molecular pathology and the 2015 WHO classification. Front Oncol. 7:1932017. View Article : Google Scholar : PubMed/NCBI
5	Kalari KR, Rossell D, Necela BM, Asmann YW, Nair A, Baheti S, Kachergus JM, Younkin CS, Baker T, Carr JM, et al: Deep sequence analysis of non-small cell lung cancer: Integrated analysis of gene expression, alternative splicing, and single nucleotide variations in lung adenocarcinomas with and without oncogenic KRAS mutations. Front Oncol. 2:122012. View Article : Google Scholar : PubMed/NCBI
6	Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current therapies and new targeted treatments. Lancet. 389:299–311. 2017. View Article : Google Scholar : PubMed/NCBI
7	Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Sosman JA, Atkins MB, Leming PD, et al: Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab. JAMA Oncol. 5:1411–1420. 2019.(Online ahead of print). View Article : Google Scholar : PubMed/NCBI
8	Shah MY, Ferrajoli A, Sood AK, Lopez-Berestein G and Calin GA: Microrna therapeutics in cancer-an emerging concept. EBioMedicine. 12:34–42. 2016. View Article : Google Scholar : PubMed/NCBI
9	Buchan JR and Parker R: Molecular biology. The two faces of miRNA. Science. 318:1877–1878. 2007. View Article : Google Scholar : PubMed/NCBI
10	Goh JN, Loo SY, Datta A, Siveen KS, Yap WN, Cai W, Shin EM, Wang C, Kim JE, Chan M, et al: microRNAs in breast cancer: Regulatory roles governing the hallmarks of cancer. Biol Rev Camb Philos Soc. 91:409–428. 2016. View Article : Google Scholar : PubMed/NCBI
11	Farazi TA, Spitzer JI, Morozov P and Tuschl T: miRNAs in human cancer. J Pathol. 223:102–115. 2011. View Article : Google Scholar : PubMed/NCBI
12	Henry JC, Azevedo-Pouly ACP and Schmittgen TD: MicroRNA replacement therapy for cancer. Pharm Res. 28:3030–3042. 2011. View Article : Google Scholar : PubMed/NCBI
13	Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, Chen Y, Xu L, Zen K, Zhang C and Shen H: Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol. 28:1721–1726. 2010. View Article : Google Scholar : PubMed/NCBI
14	Li J, Yu T, Cao J, Liu L, Liu Y, Kong HW, Zhu MX, Lin HC, Chu DD, Yao M and Yan MX: MicroRNA-148a suppresses invasion and metastasis of human non-small-cell lung cancer. Cell Physiol Biochem. 37:1847–1856. 2015. View Article : Google Scholar : PubMed/NCBI
15	He Q, Fang Y, Lu F, Pan J, Wang L, Gong W, Fei F, Cui J, Zhong J, Hu R, et al: Analysis of differential expression profile of miRNA in peripheral blood of patients with lung cancer. J Clin Lab Anal. 33:e230032019. View Article : Google Scholar : PubMed/NCBI
16	Cancer Genome Atlas Research Network, ; Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C and Stuart JM: The cancer genome atlas pan-cancer analysis project. Nat Genet. 45:1113–1120. 2013. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Zhou Q, Huang SX, Zhang F, Li SJ, Liu C, Xi YY, Wang L, Wang X, He QQ, Sun CC and Li DJ: MicroRNAs: A novel potential biomarker for diagnosis and therapy in patients with non-small cell lung cancer. Cell Prolif. 50:e123942017. View Article : Google Scholar : PubMed/NCBI
19	Petrek H and Yu AM: MicroRNAs in non-small cell lung cancer: Gene regulation, impact on cancer cellular processes, and therapeutic potential. Pharmacol Res Perspect. 7:e005282019. View Article : Google Scholar : PubMed/NCBI
20	Bica-Pop C, Cojocneanu-Petric R, Magdo L, Raduly L, Gulei D and Berindan-Neagoe I: Overview upon miR-21 in lung cancer: Focus on NSCLC. Cell Mol Life Sci. 75:3539–3551. 2018. View Article : Google Scholar : PubMed/NCBI
21	Wei W, Dong Z, Gao H, Zhang YY, Shao LH, Jin LL, Lv YH, Zhao G, Shen YN and Jin SZ: MicroRNA-9 enhanced radiosensitivity and its mechanism of DNA methylation in non-small cell lung cancer. Gene. 710:178–185. 2019. View Article : Google Scholar : PubMed/NCBI
22	Jiang Q, Yuan Y, Gong Y, Luo X, Su X, Hu X and Zhu W: Therapeutic delivery of microRNA-143 by cationic lipoplexes for non-small cell lung cancer treatment in vivo. J Cancer Res Clin Oncol. 145:2951–2967. 2019. View Article : Google Scholar : PubMed/NCBI
23	Zhu X, Liu X, Liu Y, Chang W, Song Y and Zhu S: Uncovering the potential differentially expressed miRNAs and mRNAs in ischemic stroke based on integrated analysis in the gene expression omnibus database. Eur Neurol. 9:404–414. 2020. View Article : Google Scholar : PubMed/NCBI
24	Yang B, Jing C, Wang J, Guo X, Chen Y, Xu R, Peng L, Liu J and Li L: Identification of microRNAs associated with lymphangiogenesis in human gastric cancer. Clin Transl Oncol. 16:374–379. 2014. View Article : Google Scholar : PubMed/NCBI
25	Li H, Fan J, Yin Z, Wang F, Chen C and Wang DW: Identification of cardiac-related circulating microRNA profile in human chronic heart failure. Oncotarget. 7:33–45. 2016. View Article : Google Scholar : PubMed/NCBI
26	Mishra J, Kumar A, Sinha A, Das S and Srivastava A: Ingenuity in pattern recognition: A novel bioinformatics approach towards lung cancer identification. Int J Bioinform Res Appl. 6:531–541. 2010. View Article : Google Scholar : PubMed/NCBI
27	Blomme B, Heindryckx F, Stassen JM, Geerts A, Colle I and Van Vlierberghe H: Serum protein N-glycan alterations of diethylnitrosamine-induced hepatocellular carcinoma mice and their evolution after inhibition of the placental growth factor. Mol Cell Biochem. 372:199–210. 2013. View Article : Google Scholar : PubMed/NCBI
28	Goldstein B, Trivedi M and Speth RC: Alterations in gene expression of components of the renin-angiotensin system and its related enzymes in lung cancer. Lung Cancer Int. 2017:69149762017. View Article : Google Scholar : PubMed/NCBI
29	Parsana P, Amend SR, Hernandez J, Pienta KJ and Battle A: Identifying global expression patterns and key regulators in epithelial to mesenchymal transition through multi-study integration. BMC Cancer. 17:4472017. View Article : Google Scholar : PubMed/NCBI
30	Chen L, Chen DT, Kurtyka C, Rawal B, Fulp WJ, Haura EB and Cress WD: Tripartite motif containing 28 (Trim28) can regulate cell proliferation by bridging HDAC1/E2F interactions. J Biol Chem. 287:40106–40118. 2012. View Article : Google Scholar : PubMed/NCBI
31	Zaman MM, Nomura T, Takagi T, Okamura T, Jin W, Shinagawa T, Tanaka Y and Ishii S: Ubiquitination-deubiquitination by the TRIM27-USP7 complex regulates tumor necrosis factor alpha-induced apoptosis. Mol Cell Biol. 33:4971–4984. 2013. View Article : Google Scholar : PubMed/NCBI
32	Versteeg GA, Benke S, Garcia-Sastre A and Rajsbaum R: InTRIMsic immunity: Positive and negative regulation of immune signaling by tripartite motif proteins. Cytokine Growth Factor Rev. 25:563–576. 2014. View Article : Google Scholar : PubMed/NCBI
33	Zhu L, Qin C, Li T, Ma X, Qiu Y, Lin Y, Ma D, Qin Z, Sun C, Shen X, et al: The E3 ubiquitin ligase TRIM7 suppressed hepatocellular carcinoma progression by directly targeting Src protein. Cell Death Differ. 27:1819–1831. 2020. View Article : Google Scholar : PubMed/NCBI
34	Jin J, Lu Z, Wang X, Liu Y, Han T, Wang Y, Wang T, Gan M, Xie C, Wang J and Yu B: E3 ubiquitin ligase TRIM7 negatively regulates NF-kappa B signaling pathway by degrading p65 in lung cancer. Cell Signal. 69:1095432020. View Article : Google Scholar : PubMed/NCBI
35	Hayden MS and Ghosh S: Shared principles in NF-kappaB signaling. Cell. 132:344–362. 2008. View Article : Google Scholar : PubMed/NCBI
36	Park MH and Hong JT: Roles of NF-κB in cancer and inflammatory diseases and their therapeutic approaches. Cells. 5:152016. View Article : Google Scholar : PubMed/NCBI
37	Bassères DS, Ebbs A, Levantini E and Baldwin AS: Requirement of the NF-kappaB subunit p65/RelA for K-Ras-induced lung tumorigenesis. Cancer Res. 70:3537–3546. 2010. View Article : Google Scholar